Elizabeth Rosenberg

Statistics

Publications

Citations

3.1K

H-Index

Active since

1988

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Virginia Commonwealth University

University of Wisconsin–Madison

MSD (Belgium)

Merck Biopharma Co., Ltd. (Japan)

Elizabeth Rosenberg is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacotherapy, and bone metabolism.

Publications per year

1988–2017

Publications

Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion

Sarah E. Golding, Elizabeth Rosenberg, Nicholas C.K. Valerie et al. · Molecular Cancer Therapeutics · 2009 · 389 citations · Full text

Medicine, Cancer Biology, Oncology +14

CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease

Stephen I. Rennard, David C. Dale, James F. Donohue et al. · American Journal of Respiratory and Critical Care Medicine · 2015 · 258 citations

Medicine, Pharmacology, Pharmacotherapy +16

ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation

Laura Biddlestone-Thorpe, Elizabeth Rosenberg, Jason M. Beckta et al. · Clinical Cancer Research · 2013 · 222 citations

Medicine, Oncology, Pharmacology +16

Extracellular Signal-Related Kinase Positively Regulates Ataxia Telangiectasia Mutated, Homologous Recombination Repair, and the DNA Damage Response

Sarah E. Golding, Elizabeth Rosenberg, Steven J. Neill et al. · Cancer Research · 2007 · 190 citations

Life Sciences, Cell Biology, Molecular Biology +17

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Five years of continued therapy in a phase 2 study

Bente Langdahl, Neil Binkley, Henry G. Bone et al. · Journal of Bone and Mineral Research · 2012 · 160 citations

Medicine, Pharmacotherapy, Bone Metabolism +16

1–5 of 46